IL129143A0 - Insulin c-peptides - Google Patents

Insulin c-peptides

Info

Publication number
IL129143A0
IL129143A0 IL12914397A IL12914397A IL129143A0 IL 129143 A0 IL129143 A0 IL 129143A0 IL 12914397 A IL12914397 A IL 12914397A IL 12914397 A IL12914397 A IL 12914397A IL 129143 A0 IL129143 A0 IL 129143A0
Authority
IL
Israel
Prior art keywords
peptides
atpase activity
fragment
sequence
insulin
Prior art date
Application number
IL12914397A
Other languages
English (en)
Original Assignee
Creative Peptides Sweden Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creative Peptides Sweden Ab filed Critical Creative Peptides Sweden Ab
Publication of IL129143A0 publication Critical patent/IL129143A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
IL12914397A 1996-09-27 1997-09-26 Insulin c-peptides IL129143A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9603533A SE520392C2 (sv) 1996-09-27 1996-09-27 Specifika peptider för behandling av diabetes mellitus
PCT/GB1997/002627 WO1998013384A1 (en) 1996-09-27 1997-09-26 Insulin c-peptides

Publications (1)

Publication Number Publication Date
IL129143A0 true IL129143A0 (en) 2000-02-17

Family

ID=20404052

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12914397A IL129143A0 (en) 1996-09-27 1997-09-26 Insulin c-peptides

Country Status (24)

Country Link
US (1) US6610649B2 (no)
EP (1) EP0938503B1 (no)
JP (1) JP2001500893A (no)
KR (1) KR20000048643A (no)
AT (1) ATE347562T1 (no)
AU (1) AU741901B2 (no)
BG (1) BG103362A (no)
BR (1) BR9711573A (no)
CA (1) CA2266416C (no)
CZ (1) CZ108599A3 (no)
DE (1) DE69737065T2 (no)
DK (1) DK0938503T3 (no)
ES (1) ES2278394T3 (no)
HU (1) HUP0000432A3 (no)
IL (1) IL129143A0 (no)
IS (1) IS5008A (no)
NO (1) NO991483L (no)
NZ (1) NZ335231A (no)
PL (1) PL332494A1 (no)
RU (1) RU2206336C2 (no)
SE (1) SE520392C2 (no)
SK (1) SK39499A3 (no)
TR (1) TR199900694T2 (no)
WO (1) WO1998013384A1 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0022342D0 (en) 2000-09-12 2000-10-25 Creative Peptides Sweden Ab Reduction of the electrocardiographic QT interval
DE10055857A1 (de) * 2000-11-10 2002-08-22 Creative Peptides Sweden Ab Dj Neue pharmazeutische Depotformulierung
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
JP5452843B2 (ja) * 2003-01-06 2014-03-26 エミスフィアー テクノロジーズ インコーポレイテッド 夜間の経口インスリン治療
US20050026826A1 (en) * 2003-01-17 2005-02-03 Margarethe Hoenig Feline proinsulin, insulin and constituent peptides
US20050203001A1 (en) * 2004-03-05 2005-09-15 Emisphere Technologies, Inc. Oral insulin therapies and protocol
GB0323979D0 (en) 2003-10-13 2003-11-19 Creative Peptides Sweden Ab Therapeutic applications for c-peptide
US7557081B2 (en) * 2004-05-27 2009-07-07 Essential Skincare, Llc Alpha-1-acid glycoprotein for the treatment of diabetes
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
GB0601950D0 (en) * 2006-01-31 2006-03-15 Creative Peptides Sweden Ab Compositions and methods of treating diabetes
EP2054437A2 (en) * 2006-08-07 2009-05-06 Teva Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
US20100292132A1 (en) * 2007-09-11 2010-11-18 Dorian Bevec Use of insulin c-peptide, alone or in combination with glp-1, as a therapeutic agent
GB0723250D0 (en) * 2007-11-28 2008-01-09 Univ Leeds Compositions and methods for reducing macrovascular complications in diabetic patients
US8680263B2 (en) 2008-09-19 2014-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
EP2334338A2 (en) * 2008-09-19 2011-06-22 Nektar Therapeutics Polymer conjugates of c-peptides
US8410049B2 (en) * 2009-10-28 2013-04-02 Cebix Methods and kits for preventing hypoglycemia
CN103119055A (zh) 2010-05-17 2013-05-22 塞比克斯公司 聚乙二醇化c肽
CA2827029C (en) 2011-02-11 2019-07-02 The Regents Of The University Of Michigan Tripeptide compositions and methods
CN104220086A (zh) 2011-11-17 2014-12-17 塞比克斯股份公司 Peg化的c-肽
RU2522897C1 (ru) * 2013-04-16 2014-07-20 Закрытое акционерное общество "ФАРМ-ХОЛДИНГ" Твердая кишечнорастворимая лекарственная форма с-пептида проинсулина для перорального применения (варианты) и способ ее получения (варианты)
KR101676542B1 (ko) * 2014-12-30 2016-11-16 건국대학교 산학협력단 프로인슐린의 면역학적 용도
CN104888201B (zh) * 2015-06-29 2018-04-27 齐锦生 用于防治糖尿病及其慢性并发症的肽类药物
EP3570875B1 (en) 2017-02-06 2022-07-06 Biotempt B.V. Peptide modulators of the interaction between human c-peptide and human elastin receptor for therapeutic use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU166913B (no) * 1972-05-15 1975-06-28
JPS5210872B2 (no) * 1973-07-14 1977-03-26
JPS55105653A (en) * 1978-10-02 1980-08-13 Shionogi & Co Ltd Tyrosyl c-peptides
CA1176158A (en) 1981-08-27 1984-10-16 Ronald E. Chance Pharmaceutical formulations comprising human insulin and human c-peptide
DE3326473A1 (de) 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
US4581165A (en) * 1984-06-14 1986-04-08 Eli Lilly And Company Anti-diabetic compounds
US5104854A (en) 1989-02-01 1992-04-14 Washington University Antiviral peptides
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
US5364757A (en) 1990-05-21 1994-11-15 Administrators Of The Tulane Educational Fund Methods of supporting a diagnosis of systemic lupus erythematosus
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
JPH05268982A (ja) 1992-03-27 1993-10-19 Hoechst Japan Ltd 骨形成作用を有する新規な蛋白質およびその製造法
DE69327239T2 (de) 1992-04-13 2000-05-11 Oklahoma Med Res Found Methoden and reagentien zur diagnose von autoantikörpern
WO1994025071A1 (en) 1993-05-05 1994-11-10 Keith Rose Polyoxime compounds and their preparation
AT400723B (de) 1993-08-27 1996-03-25 Biomay Prod & Handel Rekombinante alternaria alternata allergene
WO1996001846A1 (en) 1994-07-08 1996-01-25 Trustees Of Dartmouth College Proinsulin peptide compounds for detecting and treating type i diabetes
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
GB9422175D0 (en) 1994-11-03 1994-12-21 Univ Dundee Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof
GB9509164D0 (en) 1995-05-05 1995-06-28 Smithkline Beecham Plc Novel compounds
AU728186B2 (en) 1996-03-15 2001-01-04 Corixa Corporation Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
US6150500A (en) 1996-07-12 2000-11-21 Salerno; John C. Activators of endothelial nitric oxide synthase

Also Published As

Publication number Publication date
IS5008A (is) 1999-03-23
DE69737065T2 (de) 2007-06-28
RU2206336C2 (ru) 2003-06-20
JP2001500893A (ja) 2001-01-23
CZ108599A3 (cs) 1999-08-11
BR9711573A (pt) 2000-01-18
SE9603533L (sv) 1998-03-28
CA2266416A1 (en) 1998-04-02
WO1998013384A1 (en) 1998-04-02
KR20000048643A (ko) 2000-07-25
TR199900694T2 (xx) 1999-06-21
NO991483D0 (no) 1999-03-26
AU741901B2 (en) 2001-12-13
BG103362A (en) 2000-05-31
CA2266416C (en) 2008-04-29
DE69737065D1 (en) 2007-01-18
US20020107175A1 (en) 2002-08-08
AU4391597A (en) 1998-04-17
PL332494A1 (en) 1999-09-13
HUP0000432A3 (en) 2000-10-30
SE9603533D0 (sv) 1996-09-27
ATE347562T1 (de) 2006-12-15
US6610649B2 (en) 2003-08-26
NO991483L (no) 1999-05-18
DK0938503T3 (da) 2007-04-10
ES2278394T3 (es) 2007-08-01
NZ335231A (en) 2000-11-24
SK39499A3 (en) 1999-10-08
HUP0000432A2 (hu) 2000-08-28
EP0938503B1 (en) 2006-12-06
EP0938503A1 (en) 1999-09-01
SE520392C2 (sv) 2003-07-01

Similar Documents

Publication Publication Date Title
IL129143A0 (en) Insulin c-peptides
ATE251642T1 (de) Biologisch aktive fragmente des glucagon ähnlichen, insulinotropen peptides
DE68929217D1 (en) Insulinotropes hormon
EP0919242A3 (en) Method for administering acylated insulin
PT915910E (pt) Analogos de exendina, processos para a sua preparacao e medicamentos que os contem
PT1171465E (pt) Analogos de petido inibidor gastrico e sua utilizacao para o tratamento de diabetes
ATE220542T1 (de) Zweiteilige kapsel zur aufnahme von pharmazeutischen zubereitungen für pulverinhalatoren
TR199902033T2 (xx) Diyabet i�in s�lfonilura-glitazon sinerjik kombinasyonlar�.
ZA975866B (en) Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases.
PT1033990E (pt) 21-hidroxi-6,19-oxidoprogesterona (21oh-6op) e a sua utilizacao como medicamento para tratar o excesso de glucocorticoides
IS1966B (is) Peptíð p277 hliðstæður og lyfjasamsetningar sem innihalda þær, til meðhöndlunar eða sjúkdómsgreiningar á sykursýki
BR9105783A (pt) Polipeptidio,processo para o tratamento em vidro de neuronios e composicoes celular e farmaceutica
WO1999064598A3 (de) Neue insulinanaloga mit erhöhter zinkbindung
AU2668400A (en) Human antibiotic proteins
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
FI971427A (fi) Peptidit ja niitä sisältävät farmaseuttiset koostumukset
EP0967276A3 (en) Anti-tumor agent comprising salmosin
WO2003072126A3 (de) Verwendung eines fibroblastenwachstumsfaktor-bindeproteins zur behandlung und diagnose von diabetischen wundheilungsstörungen
IL134137A0 (en) Methods for diagnosis and theraphy of autoimmune diseases, such as insulin dependent diabetes mellitus, involving retroviral superantigens
AU6841300A (en) Human antibodies or fragments thereof binding to hla-cw6
ATE206306T1 (de) Verwendung von 9,10-secocholesta-5,7,10(19)-trien-1,3-ol (alfacalcidol)
WO2003099863A3 (en) Resistin binding proteins, their preparation and use
DK1340507T3 (da) Anvendelse af et fibroblastvækstfaktor-bindingsprotein til behandling og diagnosticering af diabetiske sårhelingsforstyrrelser
AU1265201A (en) A novel polypeptide, a human sterol regulatory constituent binding protein cutting active protein 22 and the polynucleotide encoding the polypeptide
WO2002062996A1 (fr) Nouveau peptide physiologiquement actif et utilisation de ce peptide